×

Lilly to buy Calytrix Bio for up to $1.5 billion

By Thomson Reuters Nov 16, 2026 | 6:19 AM

Nov 16 (Reuters) – Eli Lilly has agreed to acquire Calytrix Bio for up to $1.5 billion ​in cash to expand ‌the development of treatments for rare blood cancers, the privately held biotech said on Monday.

The move is the ‌latest ​in a string of ⁠acquisitions by the ⁠Indianapolis-based pharmaceutical giant as it works to diversify beyond its blockbuster diabetes and weight-loss franchise, ​the company’s primary growth engine.

The Calytrix transaction includes an upfront ⁠payment and additional ⁠payments tied to clinical ​trial and regulatory milestones. Calytrix did ​not disclose the size of the ‌upfront payment or the deal’s expected closing date.

Calytrix’s lead candidate is an early-stage antibody treatment ⁠for essential thrombocythemia and myelofibrosis – rare blood disorders that cause the bone marrow ⁠to ‌produce excessive abnormal blood ⁠cells.

The deal is expected ​to ‌strengthen Lilly’s footprint in hematology, ​adding an ⁠experimental treatment to a business that already includes the FDA-approved blood cancer medicine Jaypirca.

(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by ​Shailesh Kuber)